CD Formulation, a leading biotechnology company in nucleic acid formulation development, is dedicated to helping drug formulation researchers overcome research challenges. We offer innovative shRNA solutions and high-quality shRNA products, supported by our professional team and advanced equipment.
Short hairpin RNA (shRNA) refers to a specific sequence designed and screened to efficiently and selectively inhibit a target gene, as well as a specific structure composed of reverse repetitive sequences separated by loop sequences. This shRNA is inserted into a corresponding expression vector, such as a lentivirus, which initiates transcription in vivo to form the hairpin structure. The hairpin structure is processed in vivo by DICER and RNase, forming siRNA that induces RNA interference to inhibit specific gene expression. shRNA typically includes a transcription promoter, an shRNA precursor sequence, and a transcription termination signal.
Fig.1 Schematic of shRNA expression cassettes and processing pathways. (Sheng P, et al., 2020)
CD Formulation's custom shRNA services enable researchers to target specific genes by designing small hairpin RNAs that effectively reduce or inhibit gene expression. These services cover sequence design, synthesis, and validation, optimizing shRNAs for cellular or in vivo experiments. They can significantly accelerate research and enhance experimental success rates in basic research, translational medicine, and drug discovery.
Our vector construction technology ensures that at least one shRNA effectively represses the expression of the target gene. The lentiviral vectors we utilize can infect cell lines that are challenging to transfect using conventional transfection reagents, including primary cells, stem cells, suspension cells, and non-dividing cells.
Fig.2 Flow chart of shRNA preparation. (CD Formulation)
First, a suitable plasmid vector is selected, and the plasmid is enzymatically digested using a specific restriction endonuclease to achieve linearization.
Synthesize single-stranded oligonucleotides featuring specific hairpin structures by designing short hairpin RNAs (shRNAs) based on the target gene sequences.
Anneal the synthesized positive and negative strand shRNA oligonucleotides to create a double-stranded structure.
The annealed double-stranded shRNA undergoes a ligation reaction with a linearized plasmid vector. Subsequently, the ligated product is introduced into E. coli for amplification through either chemical transformation or electrotransformation.
Plasmids containing shRNA are introduced into packaging cell lines for the purpose of viral packaging.
Recombinant viruses are utilized to infect target cells, thereby stabilizing shRNA expression within those cells.
Verify the inhibitory effect of shRNA on target gene expression using qPCR or Western blot analysis.
CD Formulation's shRNA synthesis platform is committed to delivering efficient and specific gene silencing tools for both research and therapeutic applications. By employing advanced synthesis technologies, we ensure the effectiveness and safety of our shRNAs.
Items | Descriptions |
---|---|
Solid Phase Synthesis Technology Platform | Chemical synthesis methods directly produce shRNA molecules using automated chemical synthesizers, providing the benefits of high efficiency and purity. |
Enzymatic Synthesis Technology Platform | Enzymatic synthesis, in contrast, depends on enzymatic manipulations, including restriction endonucleases and DNA ligases, which offer greater flexibility. |
Technology: Delivery platforms for shRNA-bound nanoparticles
Journal: Materials Science and Engineering: C
IF: 8.457
Published: 2019
Results:
shRNAs play an important role in gene silencing and hold great promise for the treatment of a wide range of genetic and infectious diseases. Delivery of naked shRNAs in blood has several drawbacks as they are fragile in nature and prone to degradation. To overcome this problem, shRNAs can be combined with nanoparticles for safe delivery. Several nanoparticles mentioned in this paper play an important role in delivering such payloads. On one hand, they protect shRNA from degradation and on the other hand, they help to penetrate this macromolecule into the cell.
Fig.3 shRNA-nanoparticle conjugate as a therapeutic approach. (Acharya R., 2019)
If you have any questions or would like more information about our shRNA services and products, please feel free to contact us.
References